



Attorney/Docket No. 8253D  
Customer No. 027683

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  
Camden, et al.

§  
§ Group Art Unit: Not Yet Assigned

Serial No.: 10/634,542

§ Examiner: Not Yet Assigned

Filed: August 5, 2003

§  
§  
§  
§  
§

For: Compounds and Methods for Use  
Thereof in the Treatment of Viral Infection

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Alexandria, VA 22313-1450.

10/28/03

DATE

Julie Schwartz

TYPE OR PRINT NAME

Julie Schwartz

SIGNATURE

Dear Sir:

Transmitted herewith is an Information Disclosure Statement; Form 1449-PTO (8 pages); and copies of newly cited foreign patent documents and non-patent literature.

☒ No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)		SMALL ENTITY		OTHER THAN A SMALL ENTITY
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA		RATE	ADDIT FEE.	RATE
TOTAL	minus	=	0		x 9	\$	OR	x 18	\$0
INDEP	minus	=	0		x 42	\$	OR	x 84	\$0
[ ]	FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						+ 140	\$	OR + 280 \$0
					TOTAL	\$	OR	TOTAL	\$0

\* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

[ ] Please charge Haynes and Boone, LLP Deposit Account No. 08-1394 in the amount of \$\_\_\_\_\_.

[ ] A check in the amount of \$\_\_\_\_\_ is attached.

[ ] The Commissioner is hereby petitioned under 37 CFR § 1.136(a) to grant any extension of time needed for timely response to the Office Action dated in the above-identified application to preserve pendency of said application.

☒ The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to Haynes and Boone, LLP Deposit Account No. 08-1394.

[ ] Any additional filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims.

☒ Any patent application processing fees under 37 C.F.R. § 1.17.

Respectfully submitted,

*Gloria L. Norberg*

Gloria L. Norberg

Registration. No. 36,706

Date: October 28, 2003

HAYNES AND BOONE, LLP

901 Main Street, Suite 3100

Dallas, Texas 75202-3789

Telephone: 512-867-8528

Facsimile: 512-867-8632

A-155580\_1.DOC



Attorney/Docket No. 8253D

Customer No. 027683

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:  
Camden, et al.

Serial No. 10/634,542

Filed: August 5, 2003

For: Compounds and Methods for Use  
Thereof in the Treatment of  
Viral Infections

§  
§  
§  
§  
§  
§  
§  
§  
§

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT**

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 CFR §1.97 and §1.98, the Examiner's attention is directed to the documents listed on the enclosed modified Form PTO-1449. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. The cited patents are listed in numerical order and are not in any order based on their pertinence.

This Information Disclosure Statement is being filed within three months of the United States filing date. No certification or fee is required (37 CFR §1.97(b)(1)).


The present application claims priority to USSN 09/670,166, filed September 26, 2000, now issued as U.S. 6,608,096, October 19, 2003. Pursuant to 37 CFR §1.98(d), copies of the references provided in the parent application, U.S. Serial No. 09/670,166, are not provided. Copies of newly cited references are provided herewith. Pursuant to the waiver of the requirement under 37 CFR §1.98(a)(2)(i) as stated in a Pre-OG Notice dated July 11, 2003, copies of only the foreign patent documents and non-patent literature listed on the enclosed Form PTO-1449 are enclosed. For the convenience of the Examiner, the newly cited references are marked with an asterisk in the enclosed Form PTO-1449.

It is requested that the Examiner fully consider the cited references and that they be cited on the front of any patent issuing from this application.

No fees are believed due for the filing of the present Information Disclosure Statement, however, should any fees be deemed necessary, the Commissioner is hereby authorized to charge any fees which may be required to Deposit Account 08-1394.

It is respectfully requested that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Respectfully submitted,

A handwritten signature in black ink that reads "Gloria L. Norberg". The signature is written in a cursive style with a large, stylized 'G' and 'L'.

Gloria L. Norberg  
Agent for Applicant  
Registration No.: 36,706

Date: October 28, 2003


HAYNES AND BOONE, LLP  
901 Main Street, Suite 3100  
Dallas, Texas 75202-3789  
Telephone: 512-867-8528  
Facsimile: 512-867-8632



Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/634,542
		<b>Filing Date</b>	August 5, 2003
		<b>First Named Inventor</b>	Camden, et al.
		<b>Group Art Unit</b>	Not Yet Assigned
		<b>Examiner Name</b>	Not Yet Assigned
<b>Sheet</b>	1	<b>of</b>	8
		<b>Attorney Docket Number</b>	8253D

U.S. PATENT DOCUMENTS					
	Exr Init.	U.S. Patent Document		Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
		5,629,341		Camden (5637)	05-13-1997
		5,656,615		Camden (5640)	08-12-1997
		5,665,713		Camden (5639)	09-09-1997
		5,665,751		Camden (5704)	09-09-1997
		5,767,138		Camden (5638D)	06-16-1998
		5,770,616		Camden (5703)	06-23-1998
		5,840,742		Camden (5704C)	11-24-1998
		5,854,231		Camden (5783)	12-29-1998
		5,872,142		Camden (5703D)	02-16-1999
		5,880,144		Camden (5638D2)	03-09-1999
		5,900,429		Camden (6496)	05-04-1999
		5,902,804		Camden (5639C)	05-11-1999
		5,908,855		Camden (5786)	06-01-1999
		5,929,099		Camden (5781)	07-27-1999
		5,932,604		Camden (5785)	08-03-1999
		5,932,609		Camden (5785D)	08-03-1999
		6,025,377		Camden (5703D2)	02-15-2000
		6,077,862		Camden (6643D)	06-20-2000
*		6,090,796		Camden (5783C)	07-18-2000
*		6,110,953		Camden (5782D)	08-29-2000
*		6,136,835		Camden (5786DR2)	10-24-2000
*		Re 37,003		Camden (5704C)	12-26-2000
*		6,177,460	B1	Camden (5785D2R)	01-23-2001
*		6,200,992	B1	Camden (5782)	03-13-2001
*		6,228,876	B1	Camden (5703D2C)	05-08-2001
*		US 2001/0002403	A1	Camden (5785D2RC)	05-31-2001
*		6,245,789	B1	Camden (7161R)	06-12-2001
*		6,251,870	B1	Camden (5785D2)	06-26-2001
*		6,262,093	B1	Camden (5638D2C)	07-17-2001
*		6,265,427	BI	Camden (5702CR)	07-24-2001
*		6,271,217	B1	Camden (6496D)	08-07-2001
*		6,290,929	B1	Camden (8183)	09-18-2001
*		US 2001/0039291	A1	Camden (5703D2CR)	11-08-2001
*		US 2001/0041678	A1	Camden (5785D2D)	11-15-2001
*		US 2001/0047015	A1	Camden (5782C)	11-29-2001
*		6,329,355	B1	Camden (6496D2)	12-11-2001
*		US 2001/0053773	A1	Camden (6496D3)	12-20-2001
*		US 2002/0019415	A1	Camden (8105D)	02-14-2002
*		6,362,207	B1	Camden (5638D2CD)	03-26-2002
*		6,380,232	B1	Quada, Jr. et al. (8252)	04-30-2002
*		6,384,049	B1	Camden (8105)	05-07-2002
*		6,407,105	B1	Quada, Jr. et al. (8250)	06-18-2002
*		6,407,131	B1	Quada, Jr. et al. (6643R7)	06-18-2002
*		6,420,411	B1	Camden, et al. (6643R10)	07-16-2002
*		6,423,734	B1	Camden (7719)	07-23-2002
*		6,423,735	B1	Camden, et al. (6643R8)	07-23-2002
Examiner Signature				Date Considered	

\* Newly cited references are marked with an asterisk.




Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/634,542
		<b>Filing Date</b>	August 5, 2003
		<b>First Named Inventor</b>	Camden, et al.
		<b>Group Art Unit</b>	Not Yet Assigned
		<b>Examiner Name</b>	Not Yet Assigned
Sheet 2 of 8	<b>Attorney Docket Number</b> 8253D		

U.S. PATENT DOCUMENTS					
	Exr Init.	U.S. Patent Document		Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code (if known)		
*		6,423,736	B1	Camden, et al. (6643R4)	07-23-2002
*		6,462,062	B1	Camden, et al (8251)	10-08-2002
*		6,479,526	B1	Camden (5638D2CDC)	11-12-2002
*		6,482,843	B1	Quada, Jr. et al (6643R)	11-19-2002
*		US 2002-0193609	A1	Quada, Jr. et al (8252D)	12-19-2002
*		6,498,188	B1	Camden (5785D2RD2)	12-24-2002
*		6,506,783	B1	Camden (6643)	01-14-2003
*		US 2003/0032664	A1	Camden (7719C)	02-13-2003
*		6,552,059	B2	Camden (5702CRC)	04-22-2003
*		US 2003/0100592	A1	Camden, et al. (8251D)	05-29-2003
*		US 2003/0149088	A1	Camden (8315C)	08-07-2003
*		6,608,096	B1	Camden, et al. (8253)	08-19-2003
*		US 2003/187046	A1	Camden (5638D2CDC2)	10-02-2003

FOREIGN PATENT DOCUMENTS							
	Exr Init.	Foreign Patent Document			Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sub>1</sub>
		Country Code	Number	Kind Code (if known)			
		PCT	WO 96/32103		Camden (5640)	10-17-1996	
		PCT	WO 96/32104		Camden (5637)	10-17-1996	
		PCT	WO 96/32107		Camden (5638)	10-17-1996	
		PCT	WO 96/32115		Camden (5639)	10-17-1996	
		PCT	WO 96/40119		Camden (5703)	12-19-1996	
		PCT	WO 96/40120		Camden (5704)	12-19-1996	
		PCT	WO 96/40122		Camden (5702)	12-19-1996	
		PCT	WO 97/05870		Camden (5784)	02-20-1997	
		PCT	WO 97/05872		Camden (5782)	02-20-1997	
		PCT	WO 97/05873		Camden (5786)	02-20-1997	
		PCT	WO 98/32440		Camden (6496)	07-30-1998	
		PCT	WO 98/51303		Camden (6642)	11-19-1998	
		PCT	WO 98/51304		Camden (6643)	11-19-1998	
		PCT	WO 99/59585		Camden (7161R)	11-25-1999	
*		PCT	WO 01/12169	A2	Camden (7719)	02-22-2001	
*		PCT	WO 01/83457	A2	Camden (8068/8069)	11-08-2001	
*		PCT	WO 01/89499	A2	Camden (8105)	11-29-2001	
*		PCT	WO 02/09715	A2	Camden (8183)	02-07-2002	
*		PCT	WO 02/09716	A2	Camden, et al. (8184)	02-07-2002	
*		PCT	WO 02/26716	A2	Quada, Jr. et al. (8250)	04-04-2002	
*		PCT	WO 02/41891	A2	Camden (8315)	05-30-2002	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
	Exr Init.		
		Pending Application of Camden, et al., Serial No. 09/676,034, filed 09/29/00. (6643R2)	
		Pending Application of Camden, et al., Serial No. 09/676,032, filed 09/29/00. (6643R5)	
		Pending Application of Camden, et al., Serial No. 09/676,031, filed 09/29/00. (6643R6)	
*		Pending Application of Camden, Serial No. 10/340,945, filed 01/13/03 (6643C)	
Examiner Signature		Date Considered	


\* Newly cited references are marked with an asterisk.



Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/634,542		
		<b>Filing Date</b>	August 5, 2003		
		<b>First Named Inventor</b>	Camden, et al.		
		<b>Group Art Unit</b>	Not Yet Assigned		
		<b>Examiner Name</b>	Not Yet Assigned		
Sheet	3	of	8	<b>Attorney Docket Number</b>	8253D

U.S. PATENT DOCUMENTS				
	Exr Init.	U.S. Patent Document		Name of Inventor or Applicant of Cited Document
		Number	Kind Code (if known)	
		2,933,502		Klopping
		3,010,968		Loux
		3,370,957		Wagner et al.
*		3,399,212		Hoover, et al.
*		3,480,642		Stedman et al.
		3,499,761		Dersch et al.
		3,541,213		Klopping
		3,669,969		Lunn
		3,738,995		Adams et al.
*		Re 28,403		Actor et al.
		3,881,014		Regel et al.
*		3,933,846		Daum
		3,956,262		Heyes et al.
*		4,001,423		Dodds
		4,046,906		Frensch et al.
*		4,053,598		Daum, et al.
*		4,086,235		Beard
		4,731,366		Munro et al.
		4,814,329		Harsanyi et al
		5,098,923		Karjalainen et al
		5,114,951		King
		5,149,527		Weisenthal
*		5,284,662		Koparkar et al.
		5,290,801		Higley et al.
		5,310,748		Wilde et al.
		5,329,012		Anderson
		5,364,875		Wilde
		5,434,163		Edlind et al.
*		5,441,742		Autant et al.
*		5,554,373		Seabrook et al.
*		5,958,950		Padia et al.
*		6,211,177	B1	Sperl et al.
Examiner Signature				Date Considered

\* Newly cited references are marked with an asterisk.



Substitute for form 1449A/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/634,542		
		<b>Filing Dat</b>	August 5, 2003		
		<b>First Named Inventor</b>	Camden, et al.		
		<b>Gr up Art Unit</b>	Not Yet Assigned		
		<b>Examiner Name</b>	Not Yet Assigned		
<b>Sheet</b>	4	<b>of</b>	8	<b>Attorney Docket Number</b>	8253D

FOREIGN PATENT DOCUMENTS						
	Exr Init.	Foreign Patent Document			Name of Inventor or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Country Code	Number	Kind Code (if known)		
		BE	667,158		Dersch (U.S. equivalent 3,499,761 supra)	11-16-1965
*		DD	136499		Martin, et al. (Abstract only)	07-11-1979
*		DD	158398		Martin, et al. (Abstract only)	01-12-1983
*		DE	2144505	A1	Schroeder, et al. (Abstract only)	03-15-1973
		EP	0617968	A1	Vacca et al.	10-05-1994
*		FR	2,046,114		Societe Dynachim (Abstract)	03-05-1971
		FR	2,155,888		Agot	10-25-1973
*		GB	1,123,317		Smith, Kline & French Laboratories	08-14-1968
		GB	1,296,561		Paget et al.	11-15-1972
*		GB	1,397,886		Mayer et al.	06-18-1975
*		IN	158878	A	Kumar et al. (Abstract only)	02-07-1987
*		IN	159210	A	Kumar et al. (Abstract only)	04-11-1987
*		JP	51042565	A2	Sawatari, et al. (Abstract only)	11-17-1975
*		JP	51034161	A2	Suenobu, et al. (Abstract)	03-23-1976
		JP	07277956		(Abstract only)	10-24-1995
		PCT	WO 94/04541		Abraham et al.	03-03-1994
*		PCT	WO 00/21504		Van Lengerich	04-20-2000
*		PCT	WO 00/50007		Patel et al.	08-31-2000
*		PCT	WO 00/13511	A1	Air Liquide Sante	03-16-2000

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
	Exr Init.	Include Name of first Author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), volume-issue number(s), page(s), date (in parentheses). If a book, also include publisher and city and/or county where published.	T <sub>1</sub>
*		Chemical Abstract, "1H-Benzimidazole-1-carboxamide, 2-amino-N-(1,1-dimethylethyl", Registry No. 70665-72-4, (1979), American Chemical Society	
*		Chemical Abstract, "Carbamic Acid", Registry No. 83601-82-5, (1982), American Chemical Society	
*		AGARWAL, et al., "Antiparasitic agents. Part XVI. Synthesis of 5(6)-substituted benzimidazole-2-carbamates as anthelmintic agents", Indian J. Chem., Sect. B, 32B(4), pp. 453-456, (1993), American Chemical Society, (abstract only)	
*		AGARWAL, et al., "Segregation of activity profile in benzimidazoles: Effect of spacers at 5(6)-position of methyl benzimidazole-2-carbamates", Z. Naturforsch., C: Biosci., 48(11-12), pp. 829-838, (1993), American Chemical Society, (abstract only)	
*		AGRAWAL, et al. "Synthesis of 2-substituted 5(6)-aroylaminobenzimidazoles as potential anthelmintics", Indian J. Chem., Sect. B, 22B(2), pp. 146-149, (1983), American Chemical Society (abstract only)	
		ATASSI, et al., "R17934-NSC 238159: A New Antitumor Drug", pp. 599-607, (1975), Europ. J. Cancer, Vol. 11, Pergamon Press.	
		AUR, "Treatment of Parasitic Infestation in Children with Malignant Neoplasms" pp. 129-131, (1971), The Journal of Pediatrics, Vol. 78, no. 1, Mosby, Inc.	
*		BEARD, "5 (6)-Benzene ring-substituted benzimidazole-2-carbamate derivative having anthelmintic activity", U.S. Patent 4,086,235 A, (1978), American Chemical Society (abstract only)	
Examiner Signature		Date Considered	

\* Newly cited references are marked with an asterisk.


O I P E J C I B F  
OCT 31 2003  
P. T. V. T. F. TRADE MARK

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/634,542		
		<b>Filing Date</b>	August 5, 2003		
		<b>First Named Inventor</b>	Camden, et al.		
		<b>Gr up Art Unit</b>	Not Yet Assigned		
		<b>Examiner Nam</b>	Not Yet Assigned		
<b>Sheet</b>	5	<b>of</b>	8	<b>Attorn y D ck t Number</b>	8253D

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
*		BEKISH, et al., "Search for active drugs from a group of benzimidazolecarbamates for the treatment of trichinosis", Vitebsk. Med. Inst., Vitebsk, USSR, Med. Parazitol. Parazit. Bolezni, pp. 32-35, (1979), American Chemical Society (abstract only)	
*		BERG et al., "Synergistic effects of photoactivated tetra(4-sulfonatophenyl)porphine and nocodazole on microtubule assembly, accumulation of cells in mitosis and cell survival.", Journal of Photochemistry and Photobiology B: Biology, Vol. 13, pp. 59-70, (1992), Elsevier Sequoia.	
*		BERG et al., "Synergistic effects of photoactivated tetra(4-sulfonatophenyl)porphine and nocodazole on microtubule assembly, accumulation of cells in mitosis and cell survival.", Journal of Photochemistry and Photobiology B: Biology, Vol. 13, pp. 59-70, (1992), American Chemical Society, (abstract only)	
		BISSERY, et al., "Docetaxel in Vivo Combination Chemotherapy", pp. 3-16, (1995), Seminars in Oncology, Vol. 22, no. 6-S13, W.B. Saunders Company.	
		BRABENDER, et al., "The Effects of Methyl[5-(2-Thienylcarbonyl)-1H-benzimidazol-2-yl]carbamate, (R 17934; NSC 238159), a New Antitumoral Drug Interfering with Microtubules", pp. 905-916, (1976), Cancer Research, Vol. 36, American Association of Cancer Research.	
		BROWN, et al., "Antiparasitic Drugs. IV. 2-(4'-Thiazolyl)-Benzimidazole, A New Anthelmintic", pp. 1764-65, (1961), Journal of American Chemical Society, American Chemical Society.	
		CARTER et al., "Drug-Tumor Interactions", pp. 362-365, (1981), Chemotherapy of Cancer, 2 <sup>nd</sup> Ed., John Wiley & Sons.	
		CARTER, "2-( $\alpha$ -Hydroxybenzyl)-Benzimidazole", pp. 277-346, (1975), Selective Inhibitors of Viral Functions, CRC Press, Inc.	
		CHIMENO, "Process for the perparation of alkyl N'-alkylcarbamoil-N-(2-benizimidazolyl) carbamates, (1987), Chemical Abstracts 107:39817, American Chemical Society.	
*		DAUM et al., "2,4-Dioxo-1, 2, 3, 4-tetrahydro-s-triazino [1,2-a] benzimidazoles", Chemical Abstract 86:155704, (1977), American Chemical Society, (abstract only)	
		DELATOUR, et al., "Embryotoxic and Antimitotic Properties in the Benzimidazole Series", pp. 505-515, (1976), Therapie, Vol. 31, No. 4, John Libbey & Co., Ltd., (English translation thereof).	
*		DIVAKAR, et al., "Synthesis and antifilarial activity of benzimidazole-2-carbamates carrying an amino acid side chain at the 5(6)-position", Indian J. Chem., Sect. (B), 28B(3), pp. 252-260, (1989), American Chemical Society (abstract only)	
*		DUBEY, et al., "Synthesis and anthelmintic activity of 5(6)-[benzimidazole-2-yl]carboxamido]- and (4-substituted piperazin-l-y) benzimidazoles", J. Med. Chem., 28(11), pp. 1748-17-50, (1985), American Chemical Society (abstract only)	
*		DUBEY, et al., "Synthesis of 4-(aryl/arylcarbonyl)amino- and 4-arylthio/arylsulfonyl-7-chloroquinolines as potential antiparasitic agents", Indian J. Chem., Sect. B, 24B(4), pp. 408-413, (1985), American Chemical Society (abstract only)	
		DUPONT, "Benlate' Fungicide", pp. 1-9, (1994), Material Safety Data Sheet, DuPont.	
		ELGEBALY, et al., "Reversal of gamma-Radiation-Induced Leukemogenesis in Mice by Immunomodulation with Thiabendazole and Dinitrofluorobenzene", pp. 811-815 (1985), Chemical Abstracts 102:217569, American Chemical Society.	
		ELGEBALY, et al., "Reversal of gamma-Radiation-Induced Leukemogenesis in Mice by Immunomodulation with Thiabendazole and Dinitrofluorobenzene", pp. 811-815 (1985), J. Natl. Cancer Inst., Oxford University Press.	
		FRIEDMAN, et al., "Interaction of Anthelmintic and Benzimidazole Derivaives with Bovine Brain Tubulin", pp. 605-614, (1978), Biochimica et Biophysica Acta, Elsevier/North-Holland Biomedical Press.	
*		GAO, et al., "Antihydatisosis drugs: synthesis of benzimidazoles", Zhongguo Yiyao Gongye Zazhi, 20(3), pp. 110-115, (1989), American Chemical Society (abstract only)	
Examiner Signature		Date Considered	

\* Newly cited references are marked with an asterisk.






Substitute for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/634,542		
		<b>Filing Date</b>	August 5, 2003		
		<b>First Named Inventor</b>	Camden, et al.		
		<b>Group Art Unit</b>	Not Yet Assigned		
		<b>Examiner Name</b>	Not Yet Assigned		
Sheet	6	of	8	<b>Attorney Docket Number</b>	8253D

	GEORGOPAPADAKOU, et al., "Human Mycoses: Drugs and Targets for Emerging Pathogens", pp. 371-373, (1994), Science, Vol. 264, American Association for the Advancement of Science.	
	GHANNOUM, et al., "Combinations of antifungal and antineoplastic drugs with interactive effects on inhibition of yeast growth", pp. 308-320, (1990), Chemical Abstracts 113:112365, American Chemical Society.	
	GRAUBAUM, et al., "Acylation of Heterocycles with Carbonic Acid Derivatives", pp. 809-815, (1982), Chemical Abstracts 98:52877, American Chemical Society.	
	GRENDAL, et al., "Novel Preparation of Benzimidazoles from N-Arylamidines. New Synthesis of Thiabendazole", pp.259-261, (1965), Journal Organic Chemistry, Vol, 30, Academic Press.	
*	GRUENDEMANN, et al. "NMR Investigations of benzheterozoles. 2. NMR Investigations of N-acylated 2-aminobenzimidazoles", pp. 21-30, (1986), Chemical Abstract 105:133247, American Chemical Society.	
*	HAYDEN, Frederick G., "Antimicrobial Agents", Goodman & Gilman's, The Pharmacological Basis of Therapeutics, Ninth Edition, (1996), pp. 1191-1193; The McGraw-Hill Companies	
*	HOOVER et al., Benzimidazolyl Ureas, Chemical Abstract 70:11697, (1969), American Chemical Society, (abstract only)	
	KATYAR, et al., "Antiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence", pp. 2086-2090, (1994), Chemical Abstracts 121:175012z, American Chemical Society.	
*	KATYAR, et al., "In Vitro Susceptibilities of the AIDS-Associated Microsporidian <i>Encephalitozoon intestinalis</i> to Albendazole, Its Sulfoxide Metabolite, and 12 Additional Benzimidazole Derivatives", Antimicrobial Agents and Chemotherapy, (1997), pp. 2729-2732, Vol. 41, No. 1, American Chemical Society.	
*	KHASANOV, et al., "Synthesis of alkyl esters of benzimidazolyl-2-carbamate acid", Inst. Khim. Rastit. Veshchestv, Tashkent, USSR, Khim. Prir. Soedin., pp. 704-706, (1979), American Chemical Society (abstract only).	
*	KUMAR, et al., "Antiparasitic agents. Part XI. Synthesis and anthelmintic activity of 1-substituted 6-/8-[2-carbomethoxyamino]benzimidazole-5-carbonylamino-9H-pyrido[3,4-b]indoles", Indian J. Chem., Sect. B, 29B(11), pp. 1077-1080, (1990), American Chemical Society, (abstract only)	
*	KUMAR, et al., "Syntheses and anthelmintic activity of alkyl 5(6)-(substituted carbamoyl)- and 5(6)-(disubstituted carbamoyl)benzimidazole-2-carbamates and related compounds", J. Med. Chem., 27(8), pp. 1083-1089, (1984), American Chemical Society (abstract only)	
	LACEY, et al., "Activity of Benzimidazole Carbamates against L1210 Mouse Leukemia Cells" Correlation with <i>in vitro</i> Tubulin Polymerization Assay", pp. 3603-3605 (1985), Biochemical Pharmacology, Vol. 34, No. 19, Pergamon Press Ltd.	
	LACEY, et al., "Structure-Activity Relationships of Benzimidazole Carbamates as Inhibitors of Mammalian Tubulin, <i>in vitro</i> ", pp. 1073-1077 (1985), Biochemical Pharmacology, Vol 34, No 7, Pergamon Press Ltd.	
	LACEY, et al., "The Role of the Cytoskeletal Protein, Tubulin, in the Mode of Action and Mechanism of Drug Resistance to Benzimidazoles", pp. 885-936, (1988), International Journal for Parasitology, Vol. 18, No. 7, Pergamon Press Ltd.	
	LAPRAS, et al. "Experimental Study of the Potential Anticancerous Properties of Parbendazole (SKF 29044)", pp. 379-397, (1975), Bull. Soc. Sci. Vet. et Med. comparee, Lyon, Vol. 77, No. 6, Societe des Sciences veterinaires et de Medecine comparee de Lyon, (in French and English translation thereof.)	
*	LATIF et al., "Relationship between the anthelmintic activity of eight derivatives of benzimidazole carbamates against Trichinella spiralis and their chemical structures," Jpn. J. Med. Sci. Biol., 46(5-6), pp. 203-214, (1993), American Chemical Society, (Abstract Only)	
Examiner Signature		Date Considered


\* Newly cited references are marked with an asterisk.



Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/634,542
		<b>Filing Date</b>	August 5, 2003
		<b>First Named Inventor</b>	Camden, et al.
		<b>Group Art Unit</b>	Not Yet Assigned
		<b>Examiner Name</b>	Not Yet Assigned
Sheet 7 of 8	<b>Attorney Docket Number</b>	8253D	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
		LESSNAU, et al., "Disseminated Strongyloides stercoralis in Human Immunodeficiency Virus-infected Patients", pp. 119-122, (1993), Chest, Vol. 104, American College of Chest Physicians.	
		LOVETT, "Immunomodulating Effects of Thiabendazole: Immunotherapeutic Efficacy in the Treatment of Murine Fibrosarcoma", pp. 5315-5316, (1979), Dissertation Abstracts International, Health Science, Immunology, Vol. 39, No. 11, U M I.	
		LUNDY, et al., "Chemoimmunotherapy of a murine fibrosarcoma: critical factors for success of combined modality therapy", pp. 339-345, (1977), Chemical Abstracts 87:161659, American Chemical Society.	
		LUNDY, et al., "Immunomodulation with Thiabendazole: A Review of Immunologic Properties and Efficacy in Combined Modality Cancer Therapy", pp. 1955-1962, (1978), Cancer Treatments Reports, Vol. 62, No. 11, U.S. Department of Health, Education, and Welfare.	
		LUNDY, et al., "Thiabendazole: A New Immunopotentiator Effective in Therapy of Murine Fibrosarcoma", pp. 132-134, (1976), Surgical Forum, Vol. 27, No. 62, American College of Surgeons.	
		MARINOVICH, et al., "Mixtures of Benomyl, Primiphos-Methyl, Dimethoate, Diazinon and Azinphos-Methyl Affect Protein Synthesis in HL-60 Cells Differently", pp 173-85, (1994), Toxicol., Vol. 94, Elsevier Science Ireland Ltd.	
		MENZEL, et al., "Effects of some systemic fungicides on viral multiplication", pp. 353-362, (1979), Chemical Abstracts 92:123231, American Chemical Society.	
		The Merck Index, Twelfth Edition, "7943: 'Procodazole", p. 1333, and "9877: 'Triprolidine", pp. 1660-1661, (1996), Merck Research Laboratories.	
		The Merck Index, Eighth Edition, "Thiabendazole", p. 1035, (1968), Merck & Co., Inc.	
*		NAIM, et al. "Studies in antiparasitic agents. Part II. Synthesis of 5-substituted 2-alkyl(aryl)carbonylaminobenzimidazoles as orally effective anthelmintics", Indian J. Chem., Sect. B, 29B(5), pp. 464-470, (1990), American Chemical Society, (abstract only)	
		NASR et al., "Computer Assisted Structure-Anticancer Activity Correlations of Carbamates and Thiocarbamates", Journal of Pharmaceutical Sciences, pp. 831-836, (1985), American Pharmaceutical Association.	
		NENE, et al., "Systemic Fungicides", pp. 208-386, (1993), Fungicides in Plant Disease Control, Third Edition, Ch. 9, International Science Publisher.	
*		NIWAS, et al. "Possible anthelmintic agents. Synthesis of 4-aryl-2, 5-dimethyl-3-(N,N-disubstituted carbamoyl)furans, substituted isoquinolino [1,2-b]quinazolines and methyl 5(6)-substituted benzimidazole-2-carbamates", Indian J. Chem., Sect. B, 24B(7), pp. 754-760, (1985), American Chemical Society (abstract only)	
		PAGET et al., "Heterocyclic Substituted Ureas. I. Immunosuppression and Virus Inhibition by Benzimidazoleureas", Journal of Medicinal Chemistry, vol. 12, pp. 1010-1015, (1969), American Chemical Society.	
		PAGET et al., "Heterocyclic Substituted Ureas. I. Immunosuppression and Virus Inhibition by Benzimidazoleureas", Chemical Abstract 72:12644, (1970), American Chemical Society, (Abstract only).	
		PAGET et al., "Antiviral and immunization reaction-suppressing compounds containing an N-heterocyclic urea compound", Chemical Abstract 73:87920, (1970), American Chemical Society, (Abstract only).	
*		PARK, "An Inquiry into the Etiology of Cancer", The American Journal of the Medical Sciences, Vol. 115, No. 5., pp. 504-520, (1898), Lippincott Williams & Wilkins.	
		Private Communication to Dr. Von Hoff from National Institute of Health, National Cancer Society (Sept. 18, 1995).	
Examiner Signature		Date Considered	

\* Newly cited references are marked with an asterisk.



Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Application Number</b>	10/634,542
				<b>Filing Date</b>	August 5, 2003
				<b>First Named Inventor</b>	Camden, et al.
				<b>Group Art Unit</b>	Not Yet Assigned
				<b>Examiner Name</b>	Not Yet Assigned
<b>Sheet</b>	8	<b>of</b>	8	<b>Attorney Docket Number</b>	8253D

*	RAJAPPA, et al., "A novel synthesis of 5-acylaminobenzimidazole-2-carbamates: Intramolecular regioselective addition to quinone-imides", Tetrahedron Lett., 24(30), pp. 3155-3158, (1983), American Chemical Society (Abstract only)	
*	RAJAPPA, et al. "Quinone imine route to benzimidazol-2-ylcarbamates. Part 1. Synthesis of open-chain and cyclic 5-acylamino derivatives", J. Chem. Res., Synop., (5), pp. 158-159, (1986), American Chemical Society (Abstract only)	
*	RAJAPPA, et al., "Selective functionalization in 2-nitro-p-phenylenediamine. Part I. Synthesis of derivatives of 5-aminobenzimidazole", Indian J. Chem., Sect B., 19B(7), pp. 533-535, (1980), American Chemical Society (Abstract only)	
	RAM, et al., "Synthesis and Biological Activity of Certain Alkyl 5-(Alkoxy carbonyl)-1H-Benzimidazole-2-carbamates and Related Derivatives: A New Class of Potential Antineoplastic and Antifilarial Agents", pp. 539-547, (1992), Journal of Medicinal Chemistry, Vol. 35, No. 3, American Chemical Society.	
*	SAWHNEY, et al., "Synthesis of some benzimidazole derivatives as potential anthelmintics", Indian J. Chem., Sect. B, 28B(7), pp. 574-578, (1989), American Chemical Society, (Abstract only)	
*	SETOI et al. "Preparation of benzamide derivatives having a vasopressin antagonistic activity", Chemical Abstract 129:67773, (1998), American Chemical Society.	
*	SOKHANENKOVA, "Characteristics of the cholinesterase system of ascarids and the effect on it of benzimidazole carbamates", Tr. Gel'mintol. Lab., Akad. Nauk SSSR, 32, pp. 154-159, (1984), American Chemical Society (Abstract only)	
*	SRIVASTAVA, et al., "Synthesis of 2,5-disubstituted benzimidazoles, 1,3,4-thiadiazoles and 3,5-diiodosalicylanilides as structural congeners of rafoxanide and closantel", Pharmazie, 45(1), pp. 34-37, (1990), American Chemical Society, (Abstract only)	
	Stedman's Medical Dictionary, 24th Edition, "Leukemia", pp. 777-778, (1983), Williams & Wilkins.	
	TANNEBERG, et al., "Substituted Benzimidazolecarbamates", p. 7, (1985), Chemical Abstracts 102:24617, American Chemical Society.	
	TEICHER, et al., "Potentiation of Cytotoxic Therapies by TNP-470 and Minocycline in Mice Bearing EMT-6 Mammary Carcinoma", pp 227-236, (1995), Breast Cancer Research and Treatment, Vol. 36, Kluwer Academic Publishers.	
	THOMSON, "Fungicides", pp. 154, 121, 123, (1993-1994 Revision), Agricultural Chemicals Book IV, Thomson Publications.	
	VERGIEVA, "Carbendazim teratogenic activity of rats", pp. 333-339, (1982) Chemical Abstracts 98:66765, American Chemical Society.	
*	VISEN, et al., "Speed of action of methyl 5(6)-[4-(2-pyridyl)]piperazinocarbamoylbenzimidazole-2-carbamate, mebendazole and thiabendazole against experimental hookworm infections", Indian J. Exp. Bio., 25(10), pp. 695-699, (1987), American Chemical Society (Abstract only)	
Examiner Signature		Date Considered

\* Newly cited references are marked with an asterisk.